Clinical Trial Update: Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial of Q901, a selective CDK7 inhibitor from Qurient, is recruiting for advanced or metastatic solid tumors.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• Q901 (CDK7 inhibitor)

Snippet

Sponsor: Qurient Co., Ltd. | Conditions: Advanced Cancer, Metastatic Cancer | Phase 1, Phase 2 | Status: RECRUITING